152 related articles for article (PubMed ID: 35181001)
1. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
Tsutani Y; Ito M; Shimada Y; Ito H; Ikeda N; Nakayama H; Okada M
J Thorac Cardiovasc Surg; 2022 Nov; 164(5):1306-1315.e4. PubMed ID: 35181001
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
4. High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy.
Wang L; Wang X; Huang M; Yan S; Li S; Lv C; Wu N; Yang Y
Interact Cardiovasc Thorac Surg; 2021 Aug; 33(3):395-401. PubMed ID: 33880525
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
Isaka T; Ito H; Nakayama H; Yokose T; Katayama K; Yamada K; Masuda M
Mol Diagn Ther; 2019 Oct; 23(5):657-665. PubMed ID: 31347029
[TBL] [Abstract][Full Text] [Related]
6. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer.
Tsutani Y; Miyata Y; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1179-85. PubMed ID: 25112928
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
Kamigaichi A; Mimae T; Tsubokawa N; Miyata Y; Adachi H; Shimada Y; Ito H; Ikeda N; Okada M
Ann Thorac Surg; 2024 Apr; 117(4):743-751. PubMed ID: 36739066
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
[TBL] [Abstract][Full Text] [Related]
9. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
10. Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in
Li Q; Ma L; Qiu B; Wen Y; Liang W; Hu W; Chen N; Zhang T; Xu S; Chen L; Guo M; Zhao Y; Liu S; Guo J; Wang J; Wang S; Wang X; Pang Q; Long H; Liu H
Curr Oncol; 2021 Apr; 28(2):1424-1436. PubMed ID: 33916930
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer.
Tsutani Y; Imai K; Ito H; Miyata Y; Ikeda N; Nakayama H; Okada M
Ann Thorac Surg; 2022 May; 113(5):1608-1616. PubMed ID: 34186090
[TBL] [Abstract][Full Text] [Related]
13. [Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].
Shen L; Chen Y; Yun T; Guo J; Liu X; Zhang T; Liang C; Liu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):989-997. PubMed ID: 38862458
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion.
Wang S; Xu J; Wang R; Qian F; Yang W; Qiao R; Zhang B; Qian J; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Nov; 156(5):2006-2015.e2. PubMed ID: 30104070
[TBL] [Abstract][Full Text] [Related]
15. [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].
Shen C; Fang W
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):593-600. PubMed ID: 36002196
[TBL] [Abstract][Full Text] [Related]
16. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
[TBL] [Abstract][Full Text] [Related]
18. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
[TBL] [Abstract][Full Text] [Related]
19. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
20. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
